PharmaDrug has generated data showing that DMT-analogues could provide a new treatment for primary open angle glaucoma.
A company is addressing concerns over the medical application of microdosing by developing a molecule that could eliminate the potential risk of heart damage.
A recent study testing the impact of microdosing LSD has suggested the practice has no therapeutic or cognitive effects.
Last week Italy’s Constitutional Court blocked the country’s campaign calling for the decriminalisation of psychotropic substance cultivation.
A new collaboration will investigate the efficacy of EVM-101, a first-generation psychedelic treatment, for the treatment of Cancer Related Distress (CRD).
New results have demonstrated treating major depressive disorder (MDD) with psilocybin-assisted psychotherapy is effective for up to a year in some patients.
The philanthropic arm of atai Life Sciences, atai Impact, has donated $500,000 to The Multidisciplinary Association for Psychedelics (MAPS) for multi-year support of MAPS’ ongoing initiatives,...
Historically dubbed the “love drug” for its ability to induce sensual feelings and pro-social behaviour, MDMA is now being researched for a number of social and...
Some patients hospitalised with severe suicidal thoughts could benefit from ketamine treatment.
A subcommittee of the Oregon Psilocybin Advisory Board (OPAB) is considering whether to provide special protections for religious practises involving the use of psilocybin.
A group of scientists have reported findings that provide a foundation for the structure-based design of safe and effective non-hallucinogenic, rapid-acting antidepressants.
With the industry fast developing, trained professionals are vital for the delivery of psychedelic healthcare.
